Evidence map›Paper›PMID 30972177›Full record

ArticleAmerican journal of translational research2019

Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice.

Wenjing Zhou, Ji Yang, Jinzhou Zhu, Yuming Wang, Yue Wu, Liqian Xu, Yunmei Yang

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Fetuin-b Mediates Lipid Overload-Induced Hepatic Lipid Accumulation in Large Yellow Croaker (Larimichthys crocea).FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. The role of hepatokines in NAFLD.Cell metabolism · 2023
    Review
  6. Non-alcoholic fatty liver disease and liver secretome.Archives of pharmacal research · 2022
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenjing ZhouDepartment of Geriatrics, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang Province, China.
Ji YangDepartment of Geriatrics, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang Province, China.
Jinzhou ZhuDepartment of Gastroenterology, The First Affiliated Hospital of Soochow University Suzhou 215006, Jiangsu Province, China.
Yuming WangDepartment of Geriatrics, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang Province, China.
Yue WuDepartment of Geriatrics, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang Province, China.
Liqian XuDepartment of Geriatrics, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang Province, China.
Yunmei YangDepartment of Geriatrics, The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou 310003, Zhejiang Province, China.
First Affiliated Hospital Zhejiang University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous findings supported that fetuin B, a new hepatokine, may be involved in the development of hepatic steatosis, but the mechanism is still unknown. This study aims to investigate the role of fetuin B in hepatic steatosis in C57BL/6 mice and HepG2 cells. 1) We found that the administration of recombinant fetuin B aggravated hepatic lipid accumulation caused by free fatty acids (FFAs) or high fat diet,

Indexed as

AMP-activated protein kinase (AMPK)fetuin Bhepatic steatosisliver X receptor (LXR)Non-alcoholic fatty liver disease (NAFLD)

Identifiers

PMID30972177
PMCPMC6456555
OpenAlexW2989650069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.